UnitedHealthcare has revised its community and commercial plans’ coverage of erythropoiesis-stimulating agents. Effective January 1, 2020, patients who are receiving the reference epoetin alfa, Epogen or Procrit, will be required to switch to Pfizer’s biosimilar, Retacrit.
UnitedHealthcare has revised its community and commercial plans’ coverage of erythropoiesis-stimulating agents. Effective January 1, 2020, patients who are receiving the reference epoetin alfa, Epogen or Procrit, will be required to switch to Pfizer’s biosimilar, Retacrit.
Patients who wish to remain on the reference epoetin alfa will need to meet medical necessity criteria; Epogen or Procrit are considered medically necessary if a patient had minimal clinical response to Retacrit and a physician attests that a superior response would be expected from Epogen or Procrit, or if the patient has a history of intolerance to, contraindication to, or failure of Retacrit that a physician attests would not be expected with Epogen or Procrit.
Additionally, coverage for Retacrit will not require prior authorization for patients who meet diagnosis-specific criteria for indications including anemia due to chronic kidney disease, anemia due to chemotherapy, and anemia associated with myelodysplastic disease, among others.
The new policy does not apply to community plans in Kansas or Louisiana.
This revision to UnitedHealthcare’s coverage comes after the payer made a prior notable move to prefer biosimilars of anticancer drugs. In August of this year, UnitedHealthcare indicated that, starting in October, it would prefer biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, to the reference drugs, Avastin and Herceptin, respectively.
It also has made biosimilar filgrastim (Zarxio) a preferred product over follow-on filgrastim (Granix, or tbo-filgrastim), the reference filgrastim (Neupogen), and a competing biosimilar filgrastim (Nivestym).
Finally, a representative from UnitedHealthcare previously told The Center for Biosimilars® in an email that it planned to add biosimilar infliximab (Inflectra) to a preferred position along with the brand-name infliximab (Remicade).
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.